Therapeutic management of systemic sclerosis;Prise en charge thérapeutique de la sclérodermie systémique

Presse Medicale

Volumn 35, Issue 12 C2, 2006, Pages 1975-1982

  Mouthon, Luc ^a,b   Berezné, Alice ^a   Poiraudeau, Serge ^a   Guillevin, Loïc ^a,b  

^a Faculté de Médecine Paris Descartes ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN II ANTAGONIST; ANTIARRHYTHMIC AGENT; BERAPROST; BLOOD CLOTTING FACTOR 13; BOSENTAN; BUCILLAMINE; CALCITRIOL; CALCIUM CHANNEL BLOCKING AGENT; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOMPERIDONE; ERYTHROMYCIN; GAMMA INTERFERON; ILOPROST; IMATINIB; KETOTIFEN FUMARATE; METHOTREXATE; METOCLOPRAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PENICILLAMINE; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; RECOMBINANT RELAXIN; SITAXSENTAN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNINDEXED DRUG; UNIPROST;

ARTHROPATHY; DISEASE ASSOCIATION; DRUG EFFICACY; EXERCISE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; KIDNEY FAILURE; MYOPATHY; ORTHOSIS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PHYSIOTHERAPY; PULMONARY HYPERTENSION; RENAL CRISIS; REVIEW; STEM CELL TRANSPLANTATION; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

EID: 33845500319     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74932-6     Document Type: Review

References (38)

1. Servettaz A, Agard C, Tamby M, Guilpain P, Guillevin L, Mouthon L. Physiopathologie de la sclérodermie systémique : état des lieux sur une affection aux multiples facettes. Presse Med. 2006; sous presse.
2. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA, Jr., Lucas M, Michet CJ et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005; 118(1): 2-10.
3. Steen VD, Medsger TA, Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000; 43(11): 2437-44.
4. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 1999; 42(6): 1194-203.
5. Ogawa T, Ogawa K, Ogura T, Akutsu M, Saito E. Successful treatment with bucillamine for intractable interstitial lung disease in systemic sclerosis. Arthr Rheum. 2000; 43: S317.
6. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000; 132(11): 871-9.
7. Grassegger A, Schuler G, Hessenberger G, Walder-Hantich B, Jabkowski J, MacHeiner W et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol. 1998; 139(4): 639-48.
8. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992; 326(16): 1055-8.
9. Hulshof MM, Bavinck JN, Bergman W, Masclee AA, Heickendorff L, Breedveld FC et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol. 2000; 43(6): 1017-23.
10. Guillevin L, Euller-Ziegler L, Chouvet B, De Gery A, Chassoux G, Lafay P et al. Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up. Presse Med. 1985; 14(46): 2327-9.
11. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001; 44(11): 2653-64.
12. Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: a 1 year double blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis. 1979; 38: 356-61.
13. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005; 353(21): 2229-42.
14. Caskey FJ, Thacker EJ, Johnston PA, Barnes JN. Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet. 1997; 349(9052): 620.
15. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005; 353(13): 1412-3.
16. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005; 115(10): 2811-21.
17. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006; 354(25): 2667-76.
18. Kahan A, Weber S, Amor B, Saporta L, HodaraM, Degeorges M. [Controlled study of nifedipine in the treatment of Raynaud's phenomenon]. Rev Rhum Mal Osteoartic. 1982; 49(5): 337-43.
19. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994; 120(3): 199-206.
20. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest. 2001; 108(2): 241-50.
21. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004; 50(12): 3985-93.
22. Snyder MJ, Jacobs MR, Grau RG, Wilkes DS, Knox KS. Resolution of severe digital ulceration during a course of Bosentan therapy. Ann Intern Med. 2005 May 3; 142(9): 802-3. No abstract available.
23. Launay D, Diot E, Pasquier E, Mouthon L, Boullanger N, Fain O et al. Le bosentan dans le traitement des ulcères digitaux évolutifs au cours de la sclérodermie (9 cas). Presse Med. 2006; 35: 587-92.
24. Steen VD, Medsger TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthr Rheum. 1998; 41(9): 1613-19.
25. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001; 44(6): 1351-8.
26. Denton CP, Sweny P, Abdulla A, Black CM. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol. 1994; 33(1): 90-2.
27. Filaci G, Cutolo M, Scudeletti M, Castagneto C, Derchi L, Gianrossi R et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford). 1999; 38(10): 992-6.
28. Mouthon L, Berezné A, Brauner M, Kambouchner M, Guillevin L, Valeyre D. Pneumopathie infiltrante diffuse de la sclérodermie systémique. Presse med. 2006; 1943-51.
29. Maas D, Schramm A, Jackle B, Raif W, Schubothe H. [Progressive systemic sclerosis - long-term treatment with azathioprin (author's transl)]. Immun Infekt. 1979; 7(5): 165-9.
30. Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol. 2005; 141(1): 1-9.
31. Furst D, McSweeney P, Nash R, Holmberg L, Viganego F, Nelson I et al. High-dose immunosuppressive therapy (HDIT) with autologous stem cell transplantation (SCT) for systemic sclerosis (SSc): results on the first 8 patients. Arthr Rheum. 2000; 43: S392.
32. Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford). 2001; 40(1): 84-88.
33. Rook AH, Freundlich B, Jegasothy BV, Perez MI, Barr WG, Jimenez SA et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol. 1992; 128(3): 337-46.
34. Morton SJ, Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxford). 2000; 39(8): 865-9.
35. Klyscz T, Rassner G, Guckenberger G, Junger M. Biomechanical stimulation therapy. A novel physiotherapy method for systemic sclerosis. Adv Exp Med Biol. 1999; 455: 309-16.
36. Kaada B. Successful treatment of esophageal dysmotility and Raynaud's phenomenon in systemic sclerosis and achalasia by transcutaneous nerve stimulation. Increase in plasma VIP concentration. Scand J Gastroenterol. 1987; 22(9): 1137-46.
37. Pizzo G, Scardina GA, Messina P. Effects of a nonsurgical exercise program on the decreased mouth opening in patients with systemic scleroderma. Clin Oral Investig. 2003; 7(3): 175-8.
38. Seeger MW, Furst DE. Effects of splinting in the treatment of hand contractures in progressive systemic sclerosis. Am J Occup Ther. 1987; 41(2): 118-21.